about
Evidence-based Recommendations for the Management of Comorbidities in Rheumatoid Arthritis, Psoriasis, and Psoriatic Arthritis: Expert Opinion of the Canadian Dermatology-Rheumatology Comorbidity InitiativeMeta-analysis of tumor necrosis factor inhibitors and glucocorticoids on bone density in rheumatoid arthritis and ankylosing spondylitis trialsThe Scleroderma Patient-centered Intervention Network (SPIN) Cohort: protocol for a cohort multiple randomised controlled trial (cmRCT) design to support trials of psychosocial and rehabilitation interventions in a rare disease context.Correlations between changes in cytokines and clinical outcomes for early phase (proof of concept) trials in active diffuse systemic sclerosis using data from an imatinib study.2013 American College of Rheumatology/European League against rheumatism classification criteria for systemic sclerosis outperform the 1980 criteria: data from the Canadian Scleroderma Research Group.Office capillaroscopy in systemic sclerosis.Other manifestations of mixed connective tissue disease.Mortality related to cerebrovascular disease in systemic lupus erythematosus.Differences in clinical manifestations between childhood-onset lupus and adult-onset lupus: a meta-analysis.The efficacy of complementary and alternative medicine in the treatment of Raynaud's phenomenon: a literature review and meta-analysis.Arthritis risk after acute bacterial gastroenteritisThe Canadian systemic sclerosis oral health study: orofacial manifestations and oral health-related quality of life in systemic sclerosis compared with the general population.Treatment of systemic sclerosis complications: what to use when first-line treatment fails--a consensus of systemic sclerosis experts.Randomized, double-blind, placebo-controlled glucosamine discontinuation trial in knee osteoarthritis.Calcium channel blockers for primary Raynaud's phenomenon: a meta-analysis.2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative.Diagnosis, prevention, and management of statin adverse effects and intolerance: Canadian Working Group Consensus update.A meta-analysis of the risk of venous thromboembolism in inflammatory rheumatic diseases.New Classification Criteria for Systemic Sclerosis (Scleroderma).Association of health-related quality of life in childhood-onset systemic lupus erythematosus with ethnicity: results from a multiethnic multicenter Canadian cohort.Subcutaneous tocilizumab versus placebo in combination with disease-modifying antirheumatic drugs in patients with rheumatoid arthritis.A randomized trial of arthroscopic surgery for osteoarthritis of the knee.The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis.RFC1 80G>A is a genetic determinant of methotrexate efficacy in rheumatoid arthritis: a human genome epidemiologic review and meta-analysis of observational studies.The minimally important difference for the fatigue visual analog scale in patients with rheumatoid arthritis followed in an academic clinical practiceMusculoskeletal involvement in scleroderma.The Canadian systemic sclerosis oral health study II: the relationship between oral and global health-related quality of life in systemic sclerosis.Cervical spine involvement in rheumatoid arthritis over time: results from a meta-analysis.Items for developing revised classification criteria in systemic sclerosis: Results of a consensus exerciseThe Canadian Systemic Sclerosis Oral Health Study IV: oral radiographic manifestations in systemic sclerosis compared with the general population.Severe myositis of the hip flexors after pre-operative chemoradiation therapy for locally advanced rectal cancer: case report.Patterns and predictors of change in outcome measures in clinical trials in scleroderma: an individual patient meta-analysis of 629 subjects with diffuse cutaneous systemic sclerosisReduction in Serum Uric Acid May Be Related to Methotrexate Efficacy in Early Rheumatoid Arthritis: Data from the Canadian Early Arthritis Cohort (CATCH).Influence of Education on Disease Activity and Damage in Systemic Lupus Erythematosus: Data From the 1000 Canadian Faces of Lupus.The Frequency of Scleroderma Renal Crisis over Time: A Metaanalysis.Osteoporosis in scleroderma.Determining the Minimally Important Difference in the Clinical Disease Activity Index for Improvement and Worsening in Early Rheumatoid Arthritis Patients.The rapid kinetics of optimal treatment with subcutaneous methotrexate in early inflammatory arthritis: an observational studyIncidence and predictors of secondary fibromyalgia in an early arthritis cohort.CCL2 in the Circulation Predicts Long-Term Progression of Interstitial Lung Disease in Patients With Early Systemic Sclerosis: Data From Two Independent Cohorts.
P50
Q26801221-8B3B6859-7EAF-49F3-85CE-D34698498C9DQ27025358-39C1A594-D533-407C-AA56-BAD41F1EF472Q30542602-AEB7ECBD-55A3-4117-91A1-3B5A395C04CBQ30825417-F60DF34A-CD09-4929-AA2C-78FD8D39F590Q30853599-00251A4A-18CA-47EF-B073-35AEF8AFA378Q33266137-853A42DB-0107-445A-A2AE-8D76CEB0FE19Q33367697-899CC6D3-1C7F-4162-9146-92F85A7BA1C3Q33373805-07FA7C02-A911-4A13-9E29-7CE9480515A4Q33397369-F2DC8A9C-2415-4F38-9F56-2AAF51D8396BQ33443628-D91D8B0E-08E5-46ED-96A8-986F3DD01B3CQ33875595-95239689-EF65-4AE4-8AF3-21EF0BA203E2Q33920180-640D73CE-998D-4BCF-AF8A-E685AF8222AAQ34264860-7C7CC3FE-C84B-4154-AE3F-07D467F1EFD4Q34358122-1C152773-1F20-47A7-A150-6078C634DC35Q34368381-F72687F3-EBFC-455A-9D4A-E40312930F13Q34375158-23C4D396-F97F-45EC-83DD-DF2C456C5F07Q34387237-15421865-5C1A-4971-93AC-AB58FA0831F4Q34392922-AD268FC8-C008-4824-9906-708747B937F0Q34486879-AE975735-409D-4FDA-BE3B-A55519A6B8D9Q34498858-C0ECB0C0-B2C9-4CD9-B073-56CBC34BFAE8Q34770459-B7E2F84B-73E1-402A-94BA-274780B23BC7Q34824988-56BAA12C-6030-485E-85EC-600CEE038222Q35135831-6E54CCE3-A5F7-4E3A-A6E6-D4B9314DAD9CQ35159896-CD30E2E1-D1D2-44B0-93AA-A2F401303529Q35163376-E4021A95-B3F3-4441-A15F-337535AF314EQ35169074-34DAF39F-61D0-4938-A28E-F78FB970B895Q35214646-E49C750F-2EA9-4C7F-BD71-88E46980D137Q35668069-CEC0052A-FFAA-43ED-AA9D-D2FA07C4A60EQ35784089-F38DD4F2-742F-4A3C-BFAF-3492F466CA40Q35850289-A3AC7FA5-CD26-41D4-BA54-070C04247C01Q35965169-CFCE615E-91D9-464A-8514-1805CB06DB86Q35977294-3735A266-D537-4607-9679-35631899CC93Q35990760-69676E86-2D65-44B2-90FF-531B51E40D6EQ35998043-D42A45C3-B604-4969-8D15-8B45E0621E21Q36004760-1DEB7128-D3F5-43F9-A802-957FFADDD0A0Q36031020-1F7F95A2-03C4-45A8-92D3-9D9D8C4DDC34Q36087222-0912536E-DA06-4813-AA30-A2EB559F3D64Q36112213-8472154F-1AEC-49D9-8EB5-E8C1E84FF110Q36369191-2CA51F8B-D231-4504-BA45-E91572976979Q36391220-77E4C3C9-EB3C-418C-A580-9E0ABECD6E31
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Janet Pope
@ast
Janet Pope
@en
Janet Pope
@es
Janet Pope
@nl
Janet Pope
@sl
type
label
Janet Pope
@ast
Janet Pope
@en
Janet Pope
@es
Janet Pope
@nl
Janet Pope
@sl
prefLabel
Janet Pope
@ast
Janet Pope
@en
Janet Pope
@es
Janet Pope
@nl
Janet Pope
@sl
P1053
G-3342-2011
P106
P21
P31
P3829
P496
0000-0003-1479-5302